Icon

MYRBETRIQ (nda202611)- (25MG,50MG)

MIRABEGRON APGDI
25MG,50MG
Yes No
2030-Mar-28 2017-Jun-28
None None
None No
MYRBETRIQ is a beta-3 adrenergic agonist indicated for the treatment of: ? Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency, either alone or in combination with the muscarinic antagonist solifenacin succinate. ? Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more.
3 1 2
Total Other Developers 24
Drugs with Suitability No
25MG ** ** Up - -
50MG ** ** Up - 1
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** *** ***** ******* *********** ****-*, **** **. ***, ***, ****** - **, ******* ******** ****, *****, ******, *********** ******, ***** (***) ***
****** ***** ****** ***** ************ ******* *********** **** **. *-*/*&* *******, (******* ******** ****) ******, ******* ***** *.*. **. **, ***-******, ****-*********, *********, ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.